Cystic fibrosis drug developer Respirion Pharmaceuticals has spun out from Telethon Kids Institute with capital from an Australian government-backed initiative.
Respirion Pharmaceuticals, an Australia-based cystic fibrosis medicine spinout of research centre Telethon Kids Institute, has publicly launched with commitments of A$20m ($14.2m) from Australian government-backed Biomedical Translation Fund (MRCF BTF).
The investment, MRCF BTF’s first in the state of Western Australia, will be made in multiple tranches in collaboration with Telethon Kids Institute and the Western Australian Department of Health.
Respirion has also secured a $3m commitment from research charity Cystic Fibrosis (CF) Foundation, though it was unclear…
